Market Research Logo

Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments

Incretin-Based Drugs: Markets for Diabetes Therapies and Developing Treatments

The global market for incretin-based therapeutics was valued at nearly $11.8 billion in 2013 and $12.7 billion in 2014. This market is expected to reach $22.8 billion by 2019, with a compound annual growth rate (CAGR) of 12.4% from 2014 to 2019.

This report provides:

An overview of the global diabetes treatment market.

Analyses of global market trends, with data from 2012 to 2014, and projections of CAGRs through 2019.

Information on the field of glucagon-like peptide-1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors collectively known as incretin-based therapies, a drug category used mainly for the control of diabetes but that also have potential indications for cardiovascular treatment and even weight loss.

Drug sales earned according to therapeutic area as well as by geography.

Analysis of the market's dynamics, specifically major issues, and challenges.

Relevant intellectual property (IP) and patent analysis.


SCOPE OF REPORT

The scope of this study encompasses companies that are involved in diabetes prevention as well as detection, diagnosis and treatment. BCC Research analyzes each technology or therapy type, determines its current market status, examines its impact on future markets and presents forecasts of growth over the next five years. Technological issues, including the latest trends, are discussed.

CHAPTER 1 INTRODUCTION
STUDY GOALS AND OBJECTIVES
REASONS FOR DOING THIS STUDY
SCOPE OF REPORT
INTENDED AUDIENCE
METHODOLOGY
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC RESEARCH REPORTS
BCC RESEARCH WEBSITE
DISCLAIMER
CHAPTER 2 EXECUTIVE SUMMARY
INCRETINS FILL NEED FOR GLYCEMIC CONTROL
TRENDS IN DISPENSING AND SALES
SUMMARY TABLE GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, THROUGH 2019 ($ MILLIONS)
SUMMARY FIGURE GLOBAL MARKET FOR INCRETIN-BASED THERAPEUTICS, 2012-2019 ($ MILLIONS)
GEOGRAPHICAL SHIFTS
KEY DRIVERS
KEY CHALLENGES
KEY TRENDS
CHAPTER 3 OVERVIEW AND MARKET FORECAST
FIGURE 1 THE INCRETIN EFFECT ILLUSTRATED
FIGURE 2 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR NON-INSULIN ANTIDIABETICS, 2012 (%)
DATA ON WHERE INCRETINS FIT
FIGURE 3 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR GLP-1 RECEPTOR AGONISTS, 2012 (%)
FIGURE 4 PERCENTAGE OF DISPENSED PRESCRIPTIONS FOR DPP-4 INHIBITORS, 2012 (%)
FOR SOME, A GLP-1 FOCUS
TABLE 1 DIFFERENCES BETWEEN THE INCRETIN THERAPIES
STANDARD DIABETIC TREATMENTS
METFORMIN
SULFONYLUREAS (SU)
THIAZOLIDINEDIONE (TZD)
ALPHA-GLUCOSIDASE INHIBITORS
INSULIN TREATMENT
Long-acting Insulin
Intermediate-acting Insulin
Regular or Short-acting Insulin
Rapid-acting Insulin
TABLE 2 ADVANTAGES TO ADDING INCRETIN THERAPY
OTHER NEW TREATMENTS
DIABETES FURTHER EXPLAINED
TYPES OF DIABETES
Type 1
Type 2
Gestational Diabetes
Impaired Glucose Tolerance (IGT) and Impaired Fasting Glycemia (IFG)
CARE MODEL UPDATED WITH INCRETINS
CONDITIONS RELATED TO DIABETES
Obesity
FIGURE 5 ADA'S STANDARD OF MEDICAL CARE IN DIABETES, 2014
Cardiovascular Disease
Pancreatitis
Cancer
TABLE 3 CURRENT THINKING ON DIABETES MEDICATIONS AND CANCER RISK
Polycystic Ovary Syndrome
COMPLICATIONS AND COMORBIDITIES
TABLE 4 COMPLICATIONS/COMORBID CONDITIONS FROM DIABETES
INCRETIN THERAPIES
TABLE 5 COMMERCIALIZED INCRETIN THERAPY
GLP-1 RECEPTOR AGONISTS
COMMERCIALIZED GLP-1 RECEPTOR AGONISTS
Exenatide
Liraglutide
Dulaglutide
Albiglutide
Lixisenatide
COMMERCIALIZED DPP-4 INHIBITORS
Linagliptin
Sitagliptin
Vildagliptin
Saxagliptin
Alogliptin
Teneligliptin
Anagliptin
Gemigliptin
MARKET LANDSCAPE
TABLE 6 NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
FIGURE 6 NUMBER OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, 2014 AND 2019 (UNITS)
FIGURE 7 MARKET SHARE OF INCRETIN-BASED THERAPEUTICS, BY THERAPEUTIC AREA, 2014 AND 2019 (% OF REVENUE BY THERAPEUTIC AREA)
FIGURE 8 MARKET SHARE OF COMMERCIALIZED INCRETIN-BASED THERAPEUTICS, BY INCRETIN TYPE, 2014 AND 2019 (% OF REVENUE BY INCRETIN TYPE)
FIGURE 9 MARKET SHARE OF COMMERCIALIZED GLP-1 RECEPTOR AGONISTS, BY DOSING FREQUENCY, 2014 AND 2019 (%)
DEALS IN THE INCRETIN MARKET
TABLE 7 MAJOR AGREEMENTS FOR INCRETIN-BASED THERAPY
DEVELOPMENT
CHAPTER 4 THE DEVELOPMENT PIPELINE
REGULATORY ENVIRONMENT
PATENTS
DEVELOPMENT PIPELINE
FIGURE 10 NUMBER OF INCRETINS IN DEVELOPMENT BY PHASE, 2014
KEY GLP-1 RECEPTOR AGONISTS IN DEVELOPMENT
Exenatide Formulations (Including ICTA, RS-859/Exenatide-extended
Release, and Microsphere Formulation of Exenatide, DA-3091)
Liraglutide for Obesity (Sandexa) and for Type 1 Diabetes (NN9211)
Lixisenatide (Lyxumia and LixiLan [Combined Lixisenatide and Basal Insulin])
Semaglutide (NN9535)
CJC-1134-PC
TABLE 8 GLP-1 RECEPTOR AGONISTS IN LATE-STAGE DEVELOPMENT
TABLE 9 GLP-1 RECEPTOR AGONISTS IN EARLY-STAGE DEVELOPMENT
KEY DPP-4 INHIBITORS IN DEVELOPMENT
Saxagliptin (Onglyza/)Dapagliflozin Combination (Forxiga)
Trelagliptin
Omarigliptin
Gosogliptin (Satyor)
Gemigliptin
TABLE 10 DPP-4 INHIBITORS IN LATE-STAGE DEVELOPMENT
TABLE 11 DPP-4 INHIBITORS IN EARLY-STAGE DEVELOPMENT
DEVELOPMENT CASE STUDY: PHENOMIX
PROMISING PIPELINE CANDIDATES AND NOVEL RESEARCH
NOVEL ACTIVE DRUG CANDIDATES
Dual GLP-1/Glucagon Agonists
Glucagon Receptor Agonists
GLP-2
GPR119
TGR5
Glucokinase Activators
OTHER NOVEL RESEARCH
Department of Medicine, Imperial College London, U.K.
Orgenesis' Conversion of Liver Cells
DEVELOPMENT LANDSCAPE: OVERALL PHARMA MARKET
TABLE 12 TOP PHARMA COMPANIES BY REVENUE, 2013 ($ BILLIONS)
FIGURE 11 GEOGRAPHIC DISTRIBUTION OF PHARMACEUTICAL DRUGS, 2012 AND 2017 (PERCENT OF GLOBAL SALES)
DIABETES AS SALES TERRITORY
FIGURE 12 DIABETES-FOCUSED GEOGRAPHIC TERRITORY: NOVO NORDISK SALES, 2013 (% OF SALES)
BIOLOGICS AND GLP-1 RECEPTOR AGONIST PRODUCTION
Growth Factors
Gene Therapy
Recombinant Proteins
Monoclonal Antibodies
BIOLOGIC LANDSCAPE
TABLE 13 BIOLOGICS IN DEVELOPMENT IN THE U.S. BY THERAPEUTIC CATEGORY, 2013
PIPELINE FOR DIABETES AND DIABETES-RELATED MEDICATIONS
TABLE 14 GLOBAL PIPELINE FOR PHASE II AND III STAGE DIABETES MEDICATIONS, THROUGH 2019
TABLE 15 GLOBAL PIPELINE FOR PHASE I STAGE DIABETES MEDICATIONS, THROUGH 2019
TABLE 16 GLOBAL PIPELINE FOR DIABETES-RELATED DISORDERS, THROUGH 2019
OBESITY AS THERAPEUTIC CATEGORY
TABLE 17 GLOBAL PIPELINE FOR OBESITY, THROUGH 2019
TABLE 18 DIABETES AND DRUG DEVELOPMENT RESOURCES
CHAPTER 5 COMPANY PROFILES
ACTIVX BIOSCIENCES INC. (KYORIN PHARMACEUTICAL CO. LTD.)
AERPIO THERAPEUTICS INC.
AMPIO PHARMACEUTICALS INC.
AMUNIX
ARAIM PHARMACEUTICALS INC.
ARISAPH
ASTRAZENECA
BECTON, DICKINSON AND COMPANY
BOEHRINGER INGELHEIM GMBH
BRISTOL-MYERS SQUIBB
CEBIX INC.
CHEMOCENTRYX INC.
CODA THERAPEUTICS INC.
CONCERT PHARMACEUTICALS
CONJUCHEM
DIPEXIUM PHARMACEUTICALS INC.
DONG-A SOCIO HOLDINGS
ELI LILLY AND COMPANY
EMISPHERE TECHNOLOGIES INC.
EVOKE PHARMA INC.
FURIEX PHARMACEUTICALS INC.
GENKYOTEX S.A.
GLAXOSMITHKLINE PLC
GLYCADIA PHARMACEUTICALS
HANMI PHARMACEUTICAL CO. LTD.
ICO THERAPEUTICS INC.
INTARCIA THERAPEUTICS INC.
JOHNSON & JOHNSON
KOWA CO. LTD.
KYORIN PHARMACEUTICAL CO. LTD.
KYOWA HAKKO KIRIN CO. LTD.
LIGAND PHARMACEUTICALS INC.
LG LIFE SCIENCES LTD.
MANNKIND CORP.
MERCK
MERRION PHARMACEUTICALS LTD.
MITSUBISHI TANABE PHARMA CORP.
NEPHROGENEX INC.
NOVARTIS INTERNATIONAL AG
NOVO NORDISK A/S
ONO PHARMACEUTICALS
ORAMED PHARMACEUTICALS
OTSUKA PHARMACEUTICAL CO. LTD.
PFIZER
PHASEBIO PHARMACEUTICALS INC.
QUARK PHARMACEUTICALS INC.
ROCHE
ROYER BIOMEDICAL INC.
SANOFI
SANWA KAGAKU KENKYUSHO CO. LTD.
SATRX LLC
SIHUAN PHARMACEUTICAL HOLDINGS GROUP CO. LTD.
TAKEDA PHARMACEUTICAL CO. LTD.
TRANSITION THERAPEUTICS INC.
TRANSTECH PHARMA LLC
VIKING THERAPEUTICS INC.
ZEALAND PHARMA A/S
ZOSANO PHARMA CORP.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report